BioCryst Announces Departure of Dr. Helen Thackray
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray,...
Year: 2025
FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response
Novel PARG inhibitor FORX-428 has shown best-in-class characteristics in preclinical studiesTrial initially taking place in the U.S., following IND clearanceInitial...
GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1...
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment...
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like...
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially...
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025
Initiated a second potentially registrational study of IMVT-1402 in Graves’ disease (GD) and a potentially registrational study of IMVT-1402 in...
Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial...
Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $439 millionCARVYKTI® demonstrated positive long-term outcomes in CARTITUDE-1 study with one-third...
Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update
In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer,...
Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas
Houston Center Cleared to Commence Commercial Sales of Normal Source PlasmaState of the Art Facility has Annual Collection Capacity of...
Harvard Bioscience Announces Second Quarter 2025 Financial Results
Reports Q2 2025 Revenues of $20.5M, Gross Margin of 56.4%, and Positive Cash Provided by OperationsThird Quarter 2025 Guidance Reflects...
Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update
- Total revenues of $301,000 for quarter, and $818,000 for first six months of 2025, from sales and collaborative research...
I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers
Enrollment in the planned second dose expansion cohort completed ahead of expectationsTopline results expected in Q1 2026 Positive Phase 1b...
Sionna Therapeutics Reports Second Quarter 2025 Financial Results
Announced positive Phase 1 data for SION-719 and SION-451 demonstrating both first-in-class NBD1 stabilizers were generally well tolerated and exceeded...
FDA Clears IND for SEED Therapeutics’ RBM39 Degrader ST-01156
• First Patient Dosing Expected in Q1 2026 • Clinical Trial to Prioritize Biomarker-Selected RBM39-Dependent Cancers KING OF PRUSSIA, Pa., Aug....
BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference
NEW HAVEN, Conn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence...
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events
STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse...
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Tinlarebant granted Breakthrough Therapy Designation for Stargardt disease (STGD1) by the U.S. Food and Drug Administration (FDA)DRAGON trial completion expected...